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Abstract (250 words) 28 
Background: Substance P (SP) is involved in the pathogenesis of cough in animal models. 29 
However, few studies of humans have been reported and the roles of SP in clinical cough 30 
remain obscure. 31 
Objectives: To clarify the relevance of plasma levels of SP in patients with persistent cough. 32 
Methods: We studied 82 patients with cough persisting for at least 3 weeks and 15 healthy 33 
controls. Patients were classified as having asthmatic cough (cough variant asthma and 34 
cough-predominant asthma; n = 61) or non-asthmatic cough (n = 21; post-infectious cough, 35 
n = 6; gastroesophageal reflux disease, n = 5; idiopathic cough, n = 5; others, n = 5). 36 
Correlations were evaluated between plasma SP levels as measured with ELISA and each of 37 
methacholine airway hyperresponsiveness (airway sensitivity and airway reactivity), 38 
capsaicin cough sensitivity, sputum eosinophil and neutrophil counts, and pulmonary 39 
function. 40 
Results: Plasma SP levels were significantly elevated in patients with both asthmatic and 41 
non-asthmatic cough compared with controls (31.1 (18.0-52.2) and 30.0 (15.1-50.3) vs. 15.4 42 
(11.3-23.7) pg/ml; p = 0.003 and p = 0.038, respectively), but did not differ between the two 43 
patient groups (p = 0.90). Plasma SP levels correlated with airway sensitivity (threshold dose 44 
of methacholine) in the patients with asthmatic cough (r = -0.37, p = 0.005), but not with 45 
airway reactivity, cough sensitivity, FEV1 values or sputum eosinophil and neutrophil counts 46 
in either group. 47 
Conclusions: Increased levels of SP in plasma are associated with persistent cough in 48 
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humans, and might be related to airway sensitivity in asthmatic cough.49 
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Abbreviation list 50 
AHR: airway hyperresponsiveness 51 
CGRP: calcitonin gene-related peptide 52 
CVA: cough variant asthma 53 
FEF25-75%: forced mid-expiratory flow 54 
GERD:  gastroesophageal reflux disease 55 
RARs: rapidly adapting receptors 56 
SP: substance P57 
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Introduction 58 
Substance P (SP) is one of several neuropeptides that are widely distributed in sensory 59 
peripheral nerves [1] and in the central nervous system [2]. Ample evidence supports a role 60 
for SP in the mechanism of cough in animal models [3-5]. Although its activity in cough 61 
induction is controversial [3,6], SP elicits a sensitizing effect on the cough reflex [4,5], while 62 
conflicting results also exist [7]. 63 
A few studies have examined the relationship between SP and cough in humans. Patients 64 
with attenuated cough sensitivity associated with advanced Parkinson’s disease and 65 
aspiration pneumonia have reduced SP levels in sputum [8,9]. Substance P-immunoreactive 66 
nerve densities of the bronchial epithelium are increased in patients with cough variant 67 
asthma (CVA), compared with those of patients with classic asthma and healthy controls 68 
[10]. Levels of SP are also increased in nasal lavage fluid [11] and sputum [12] from patients 69 
with non-asthmatic cough. Furthermore, elevated numbers of calcitonin gene-related peptide 70 
(CGRP)-immunoreactive nerves in the bronchial epithelium of patients with idiopathic 71 
persistent cough correlate with cough sensitivity to inhaled capsaicin, whereas levels of SP 72 
are not elevated or correlate with cough sensitivity [13]. Yoshihara et al. have shown that 73 
plasma SP levels are elevated in patients with paroxysmal cough due to pertussis [14]. 74 
However, further information about plasma SP levels in persistent cough of other etiologies 75 
has not been reported. 76 
Cough is attributed to various causes [15-18]. Persistent cough due to asthmatic and 77 
non-asthmatic causes might involve different mechanisms, since asthmatic cough is elicited 78 
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by bronchoconstriction whereas non-asthmatic cough might be primarily ascribed to 79 
increased cough sensitivity. Although cough and bronchoconstriction often occur 80 
simultaneously, they are regarded as separate reflexes 19]. Bronchoconstrictors including 81 
methacholine provoke cough without altering the cough reflex 20]. 82 
Other than cough, evidence shows that SP functions in bronchoconstriction and airway 83 
hyperresponsiveness (AHR) [21,22]. Therefore, SP might be differently involved in the 84 
mechanisms of both asthmatic and non-asthmatic cough. Indeed, SP contents in the nasal 85 
lavage fluid of patients with non-asthmatic cough are associated with increased cough 86 
sensitivity [11], whereas in asthma, sputum levels of SP correlate with airflow obstruction 87 
[23]. 88 
Here, we compared plasma SP levels in patients with combined subacute cough (duration 89 
of 3 to 8 weeks) and chronic cough (> 8 weeks) as defined by a guideline [15] with those of 90 
healthy controls. We also examined the relationship between plasma SP levels and various 91 
clinical and functional indices to determine the roles of SP in patients with asthmatic and 92 
non-asthmatic cough.93 
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Material and Methods  94 
Participants 95 
 We studied 82 consecutive patients who were referred to the outpatient asthma and cough 96 
clinic of Kyoto University Hospital between October 2007 and August 2009 because of 97 
cough that had persisted for at least 3 weeks. None of the patients had abnormal chest 98 
radiographic findings, or had been prescribed with angiotensin-converting enzyme 99 
inhibitors, oral or inhaled corticosteroids, leukotriene receptor antagonists, or other 100 
anti-allergic drugs. None had been taking drugs that may interfere with circulating substance 101 
P levels, such as anti-histamines, angiotensin- converting enzyme inhibitors, or centrally 102 
acting drugs such as dopamine receptor agonists. All patients were either never smokers or 103 
former smokers who had smoked less than 10 pack-years and had quitted smoking for more 104 
than one year. 105 
Causes of cough were determined according to the Japanese cough guidelines [16]. In brief, 106 
patients with AHR to methacholine or reversible airflow obstruction and improvement of 107 
coughing with β2-agonists were considered as having chronic cough due to asthma. Patients 108 
with cough as the sole or predominant symptom (cough-variant or cough-predominant 109 
asthma) were included, and were categorized as having asthmatic cough. The others were 110 
categorized as having non-asthmatic cough caused by the following [16]: sinobronchial 111 
syndrome (chronic sinusitis complicated by neutrophilic airway inflammation of the lower 112 
airways) [17,24] diagnosed based on positive sinus images, and symptoms related to chronic 113 
sinusitis improved with macrolides; gastroesophageal reflux disease (GERD) based on 114 
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response to treatment with proton-pump inhibitors; post-infectious cough, based on a history 115 
of upper respiratory tract infection followed by cough that spontaneously subsided; atopic 116 
cough, based on findings suggesting an atopic predisposition or induced sputum eosinophilia 117 
as well as a response to anti-histamines [16,25]; cough due to pertussis based on the typical 118 
clinical course of pertussis and a positive antipertussis toxin antibody reaction; and 119 
idiopathic cough, for which extensive examinations and intensive therapeutic trials were 120 
negative or failed to reveal any conclusive findings. The numbers of patients who underwent 121 
more specialized and detailed examinations or assessment were as follows: 9 for thoracic 122 
CT, 4 for sinus CT, 3 for esophageal endoscopy, 3 for bronchoscopy, and 3 for ENT 123 
consultations. To compare the plasma SP levels among different causes of subacute and 124 
chronic cough, patients with cough due to multiple causes were not included in the cohort, 125 
who had asthma and GERD (n=4), postinfectious cough and GERD (n=2), asthma and 126 
sinobronchial syndrome (n=2), or sinobronchial syndrome and GERD (n=1). 127 
We also studied 15 healthy controls recruited from our hospital staff who had no history of 128 
respiratory disease. We excluded individuals with atopic dermatitis in this study, because its 129 
presence positively affects the plasma SP levels [26]. The Ethics Committee of Kyoto 130 
University approved the research protocol (approval number E-300) and written informed 131 
consent was obtained from all participants. 132 
 133 
Measurement of plasma levels of substance P 134 
Blood was sampled at presentation in all subjects. Samples were immediately centrifuged 135 
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and plasma was mixed with an equal volume of a stabilizer (Kyowa Medex Co., Ltd. KM 136 
Assay Center, Nagaizumi-cho, Shizuoka, Japan) that inhibits neutral endopeptidase [27]. The 137 
samples were frozen at -20°C. Investigators who were blinded to the clinical conditions of 138 
the patients measured plasma SP levels using a competitive ELISA method [27,28]. The 139 
sensitivity of this assay is 4.1 pg/ml. The specificity of the assay for SP measurement is 140 
100%, and the assay does not significantly cross-react with neurokinin A or neurokinin B. 141 
 142 
Sputum induction and processing 143 
Sputum was induced and processed as described by Pin [29] with slight modifications [30]. 144 
In brief, after pretreatment with salbutamol, sputum was induced by inhaling hypertonic 145 
saline (3%) solution for 15 min from an ultrasonic nebulizer. Adequate plugs of sputum were 146 
treated with 0.1% dithiothreitol (Sputasol, Oxoid Ltd., Hampshire, UK), followed by 147 
Dulbecco’s phosphate-buffered saline (PBS). Eosinophil and neutrophil percentages were 148 
determined by counting at least 400 non-squamous cells on centrifuged preparations 149 
visualized by May-Grünwald-Giemsa staining. 150 
Our primary purpose of evaluating sputum cells was to investigate the association of 151 
cellular inflammation of the airways with plasma levels of SP. Sputum cell differentials were 152 
also used for the diagnosis of disease, e.g., atopic cough. 153 
 154 
Pulmonary function test 155 
We measured forced vital capacity (FVC), FEV1, and forced mid-expiratory flow (FEF25-75%) 156 
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with a use of Chestac-65V (Chest MI Corp., Tokyo, Japan), as described [31]. 157 
 158 
Methacholine challenge test 159 
We determined AHR by measuring respiratory resistance (Rrs; cmH20/L/sec) (AstographTM; 160 
Chest, Tokyo, Japan) under continuous methacholine inhalation as described [32,33]. The 161 
index of airway sensitivity was Dmin, namely, the cumulative dose of inhaled methacholine 162 
at the inflection point where Rrs started to continuously increase. One unit of Dmin is 163 
equivalent to a dose of 1 mg/ml of methacholine inhalation for 1 min. When the respiratory 164 
resistance did not increase despite methacholine inhalation at the highest concentration, 165 
Dmin was assigned a value of 50 units, which was the total cumulative dose of 166 
methacholine. The slope of the respiratory dose-response curve (SRrs) was used as the 167 
measure of airway reactivity [33]. Fifty-nine patients with asthmatic cough and all 21 with 168 
non-asthmatic cough underwent the test. 169 
 170 
Capsaicin cough sensitivity test 171 
Cough sensitivity was tested by continuous inhalation of capsaicin as described [34] with a 172 
slight modification of capsaicin concentrations [24]. Ten doubling concentrations of 173 
capsaicin solution (0.61 - 312 µM) were inhaled until ≥5 coughs were induced. Each 174 
concentration of capsaicin was inhaled for 15 sec during tidal breathing every 60 sec. The 175 
concentration of capsaicin causing ≥5 coughs is referred to as C5 [24,34]. Fifty-nine patients 176 
with asthmatic cough and all 21 with non-asthmatic cough underwent the test. 177 
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 178 
Statistical analysis 179 
Data are expressed as median values (25th to 75th percentiles) except when noted otherwise 180 
and were analyzed using JMP 6.0 (SAS Campus Drive, Cary, NC, USA). Comparisons of 181 
two and three groups were achieved using the Mann-Whitney and Kruskal-Wallis tests, 182 
respectively, and the latter were analyzed post hoc using the Steel-Dwass test [35-37]. 183 
Categorical data were compared using the χ2 test. Correlations between data were analyzed 184 
using Spearman’s rank correlation test. P values of <0.05 were considered statistically 185 
significant. 186 
187 
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Results 187 
Characteristics of the three groups 188 
Table 1 shows the characteristics of the 61 patients with asthmatic cough, 21 with 189 
non-asthmatic cough and 15 controls. Only the ratios of sputum eosinophils significantly 190 
differed among the three groups. 191 
Cough in the non-asthmatic cough group was due to post-infection (n = 6), GERD 192 
(5), atopic cough (2), pertussis (2), sinobronchial syndrome (1) but was idiopathic in 5 193 
patients. 194 
 195 
Outcomes in patients with asthmatic and non-asthmatic cough 196 
Table 2 shows the outcomes of the two patient groups. Two of the patients with asthmatic 197 
cough were ineligible for AHR analysis since the inflection point where Rrs increased could 198 
not be determined because severe coughing was elicited. Patients with asthmatic cough were 199 
significantly more sensitive to methacholine as determined by Dmin than those with 200 
non-asthmatic cough. C5 was marginally lower in patients with non-asthmatic cough than 201 
those with asthmatic cough. 202 
 203 
Comparison of plasma SP levels among the three groups 204 
Plasma SP levels were significantly higher in patients with asthmatic and non-asthmatic 205 
cough compared with healthy controls (31.1 (18.0-52.2) and 30.0 (15.1-50.3) vs. 15.4 206 
(11.3-23.7) pg/ml), but did not significantly differ between the two patient groups (Fig. 1). 207 
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 208 
Relationships between plasma SP levels and clinical indices 209 
Plasma SP levels significantly correlated with airway sensitivity determined by Dmin only in 210 
patients with asthmatic cough (Table 3, Fig. 2). Plasma SP levels did not correlate with 211 
cough duration, airway reactivity, capsaicin cough sensitivity, spirometric indices or sputum 212 
neutrophil and eosinophil counts in either patient group (Table 3). 213 
214 
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Discussion 214 
We measured plasma level of SP in patients with subacute and chronic cough of various 215 
origins and healthy subjects. We discovered that plasma SP levels are elevated in patients 216 
with cough of asthmatic and non-asthmatic origins. We also found that plasma SP levels 217 
correlate with airway sensitivity in patients with asthmatic cough. These results indicate that 218 
SP is involved in both asthmatic and non-asthmatic cough, and its role in the mechanisms of 219 
these types of cough might differ. 220 
Substance P synthesized in the cell body of C-fibers is transported along axons towards the 221 
peripheral and central terminals, where it is stored in large-granular vesicles. C-fiber 222 
activation evokes SP release into the airway dependent on the axon reflex in guinea pigs. 223 
Airway SP causes bronchospasm, vasodilation, edema and mucus secretion, which 224 
secondarily evokes the activation of rapidly adapting receptors (RARs) in the airway, 225 
resulting in an enhanced cough reflex [5,6]. The sensitizing effect of SP on RARs has also 226 
been demonstrated in the central nervous system, especially in the nucleus tractus solitarius, 227 
which also results in an enhanced cough reflex [38,39]. While airway SP levels or expression 228 
in patients with persistent cough are conflicting [10-13,40,41], we found elevated plasma SP 229 
levels in patients with persistent asthmatic and non-asthmatic cough. 230 
We found that SP may be associated with airway sensitivity in asthmatic cough. Airway 231 
sensitivity and airway reactivity are two major components of AHR, and might have 232 
different underlying mechanisms [33,42]. Both airway sensitivity and reactivity are 233 
associated with SP. Umeno et al. reported that intravenous SP increases airway sensitivity to  234 
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histamine in guinea pigs [22] and Cheung et al. showed that inhaled SP enhances maximal 235 
airway narrowing to methacholine in patients with asthma [21]. Airway sensitivity may be 236 
determined by the strength of the stimulus that triggers the airways to constrict, such as 237 
epithelial damage, neural control and inflammatory cell numbers, while airway reactivity 238 
may be caused by the responsiveness of airways to applied stimuli such as smooth muscle 239 
contractility, viscous and elastic loads, and airway swelling [42]. Our results suggest that SP 240 
plays a role in the pathophysiology of asthmatic cough by affecting airway sensitivity. 241 
Although levels of plasma SP were higher in patients with non-asthmatic cough than in 242 
healthy controls, we found no correlation between plasma SP levels and various indices 243 
including capsaicin cough sensitivity. This is in conflict with the findings of Cho et al., who 244 
showed that SP levels in nasal lavage fluid correlate with capsaicin cough sensitivity in 245 
patients with non-asthmatic cough [11]. This discrepancy might be attributed to the different 246 
sample sources, or smaller sample size in our study. Indeed, although Cho et al. found a 247 
correlation between SP in nasal lavage fluid and cough sensitivity in all 38 of their patients 248 
with non-asthmatic cough, no correlation was evident when the patients were separated into 249 
two equal, separately analyzed groups (n = 19 for each) with increased and normal cough 250 
sensitivity [11]. 251 
The two phenotypes of asthma might involve different pathophysiological 252 
mechanisms: CVA or cough-predominant asthma and classic asthma that predominantly 253 
presents with wheezing. De Diego et al. have reported that although classic asthma and CVA 254 
have similar profiles of airway inflammatory markers, their relationships with AHR and 255 
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cough sensitivity differ [43]. Lee et al. found increased SP-immunoreactive nerve densities 256 
in patients with CVA but not in those with classic asthma [10]. Substance P is associated 257 
with neurogenic inflammation and subsequent airflow obstruction in asthma [23,44]. We 258 
found no correlation between plasma SP levels and spirometric indices, which contradicts 259 
the findings of Tomaki et al., who found a negative correlation between sputum SP levels 260 
and FEV1/FVC in patients with classic asthma [23]. This discrepancy might be attributed to 261 
the different sample sources, and less prominent airflow obstruction in our patients 262 
(FEV1/FVC of 80.3% by average) compared with those of Tomaki et al. (71.3%). 263 
Airway inflammation stimulates receptors of unmyelinated C-fibers of the vagus nerve, 264 
thus causing the release of tachykinins such as SP from the C-fibers [11,45,46]. A 265 
correlation between sputum SP levels and sputum eosinophil count has been reported in 266 
asthma [23]. Since patients with CVA show evidence of airway inflammation with increased 267 
eosinophils [47] and since non-asthmatic cough might be associated with increased 268 
neutrophils [48], we evaluated the correlation between plasma SP levels and sputum counts 269 
of eosinophils and neutrophils in each patient group. However, we found no correlation 270 
between plasma SP levels and these sputum cells in either patient group. Circulating levels 271 
of SP might not be related to cellular inflammation of the airways in patients with persistent 272 
cough. 273 
Our study has some limitations. Firstly, we could not determine whether SP levels in 274 
plasma reflect those in the airways. Moreover, although SP is widely distributed in the 275 
central and peripheral nervous system, there is increasing evidence that it may be 276 
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synthesized and released from inflammatory cells such as eosinophils, monocytes and 277 
macrophages, lymphocytes and dendritic cells [49-52]. Therefore elevated levels of SP in 278 
plasma may reflect over expression of SP in inflammatory cells as well as those in sensory 279 
nerves. Secondly, atopic dermatitis might have influenced the levels of SP in plasma [53]. 280 
Atopic dermatitis was present in eight patients with asthmatic cough but none in those with 281 
non-asthmatic cough. However, we found no difference in plasma SP levels between patients 282 
with and without atopic dermatitis (p = 0.51). Thirdly, the sample size of patients with 283 
non-asthmatic cough was small, and the etiology of their cough was diverse. We found no 284 
differences in plasma SP levels among the three most common diagnostic subgroups of 285 
non-asthmatic cough (post-infectious cough [n = 6], GERD [n = 5], and idiopathic cough [n 286 
= 5]; p = 0.196 by Kruskal-Wallis test). Future larger studies might clarify the roles of SP, 287 
especially in non-asthmatic cough. Fourthly, while success rate of sputum induction in our 288 
previous series of 407 patients with classic asthma was 73.0% [54], the success rate in the 289 
present study was lower (57/97, 59%). This may be because cough due to cough variant 290 
asthma or non-asthmatic origin such as GERD is more dry or non-productive in nature as 291 
compared with cough of classic asthma [55], and “healthy” controls do not present with 292 
sputum by definition. Fifthly, patients diagnosed as not having GERD might actually have 293 
had GERD, because the diagnosis of GERD solely depended on the response to specific 294 
therapy, not involving the gold standard for the diagnosis. The same is true for more 295 
uncommon causes of cough such as obstructive sleep apnea and tracheal collapse. 296 
Despite these limitations, the elevated plasma SP levels in patients with asthmatic 297 
 - 19 - 
and non-asthmatic cough are notable. Substance P in plasma is associated with persistent 298 
cough and it might be related to airway sensitivity in asthmatic cough. 299 
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Figure legends 453 
 454 
Figure 1. Comparison of plasma SP levels among groups. 455 
Plasma SP levels are elevated in patients with asthmatic and non-asthmatic cough compared 456 
with controls, while the two patient groups do not significantly differ. 457 
 458 
Figure 2. Correlation between plasma SP levels and airway sensitivity. 459 
Plasma SP levels negatively correlate with Dmin in asthmatic, but not in non-asthmatic 460 
cough. Logarithmic data are presented for Dmin. 461 
462 
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Table 1. Characteristics of the three subject groups 462 
 Asthmatic 
cough (n = 61 ) 
Non-asthmatic 
cough (n = 21 ) 
Healthy 
controls (n = 15 ) 
 
p values* 
Male, n 16 [26%] 5 [24%] 8 [53%] 0.10 
Age, y 52 (33-65) 49 (34-65) 43 (38-60) 0.9989  
Former smokers, n 12 [20%] 3 [14%] 2 [13%] 0.77 
FEV1/FVC, % 80.3 (74.5-84.8) 80.0(75.7-85.4) 80.6 (78.8-84.0) 0.75 
FEV1, %predicted 101.2 (90.4-111.4) 101.5 (89.1-106.9) 100.6 (90.6-108.6) 0.92 
FEF25-75, %predicted 83.7 (67.5-105.7) 93.0 (74.2-108.9) 78.3 (73.9-100.0) 0.74 
 Sputum eosinophil, %† 1.1 (0.3-4.3) 0.4 (0.2-0.9) 0.0 (0.0-0.8) 0.040‡ 
Sputum neutrophil, %† 59.6 (43.3-79.3) 58.8 (45.9-84.6) 60.0 (42.8-84.1) 0.94 
Data are expressed as medians (25th to 75th percentile) or numbers [%]. 463 
NA, not applicable. 464 
*Kruskal-Wallis or χ2 test. 465 
†Sputum induction was successful in 38 patients with asthmatic cough, 10 with non-asthmatic cough, 466 
and nine healthy controls. 467 
‡Asthmatic cough vs. controls, p = 0.07; asthmatic cough vs. non-asthmatic cough, p = 0.27. 468 
and non-asthmatic cough vs. controls, p = 0.51 by Steel-Dwass test. 469 
470 
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Table 2. Characteristics of the two patient groups 470 
 
 
Asthmatic Cough  
(n = 61 ) 
Non-asthmatic cough  
(n = 21 ) 
 
p values* 
Cough duration 12 (7-24) 8 (4-40) 0.18 
Atopy†, n 38 [63%] 11 [58%] 0.67 
Serum IgE, U/ml‡ 80.0 (28.0-190.0) 77.0 (10.0-400.0) 0.71 
Dmin, units§  2.8 (1.4-6.6) 9.8 (2.9-29.0) 0.007 
SRrs, cmH20/L/s/min§ 1.3 (0.8-2.4) 1.2 (0.5-2.2) 0.54 
C5, µM║ 9.8 (2.4-19.5) 2.4 (0.9-14.6) 0.07 
Data are expressed as medians (25th to 75th percentiles) or number [%]. NA, not applicable. 471 
*Mann-Whitney U-test or χ2 test. 472 
†Atopy was determined based on presence of specific serum IgE antibodies to at least one 473 
common inhalant allergen, including cat dander, dog dander, weed pollens, grass pollens, 474 
molds or house dust mites. Data are missing for one patient with asthmatic cough and two 475 
with non-asthmatic cough. 476 
‡Data are missing for two patients each with asthmatic and non-asthmatic cough. 477 
§Data are missing for two patients with asthmatic cough. Two patients among those with 478 
asthmatic cough were not eligible for analysis of AHR. 479 
║Data are missing for two patients with asthmatic cough. 480 
481 
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Table 3. Correlations between plasma SP levels and clinical indices in the two patient 481 
groups 482 
 Asthmatic cough Non-asthmatic cough 
 r p r p 
Cough duration 0.10 0.42 -0.24 0.29 
Serum IgE, U/ml 0.18 0.19 0.35 0.14 
FEV1/FVC, % -0.18 0.17 0.04 0.88 
FEV1, %predicted -0.02 0.88 0.12 0.62 
FEF25-75, %predicted -0.05 0.73 0.05 0.84 
Dmin, Units -0.37 0.005 0.08 0.73 
SRrs, cmH2O/L/s/min 0.01 0.93 0.05 0.85 
C5, µM 0.16 0.23 0.01 0.95 
Sputum eosinophil, % 0.15 0.36 0.09 0.80 
Sputum neutrophil, % 0.18 0.28 -0.39 0.26 
 483 


